Back to results
US 12,171,826 B2Granted
HCoV immunogenic booster composition for improving immunityagainst SARS-COV-2 infection
OwnerTimothy S. Moore, Cullen Thomas Mooreinventors
Life of this patent
Estimating the term…
Abstract
Embodiments include a method of using inactivated human cold coronaviruses (HCoVs) particularly HCoV-299E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 as a booster, for the immunization against SARS-CoV-2 infections.
Claims4
An immunogenic composition administration method comprising the steps of:
- (a) selecting a patient that has been administered an RNA or DNA based vaccine designed to produce a specific SARS-COV-2 protein;
- (b) administering to said patient at a time after administration of said RNA or DNA based vaccine of step (a), an immunologic pharmaceutical preparation of whole killed virus of two or more of the group consisting of:
- HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, wherein the specific SARS-CoV-2 protein of step (a) is a spike protein.
Dependencies are inferred from the claim text.